Want to see GB:BVXP full AI Analyst Report?
BVXP Stock Chart & Stats
1800.00 p
56.00 p(1.70%)
At close: 4:00 PM EST
1800.00 p
56.00 p(1.70%)
Day’s Range― - ―
52-Week Range1,300.00 p - 2,860.00 p
Previous CloseN/A
Volume24.00
Average Volume (3M)7.85K
Market Cap
£82.03M
Enterprise Value95.58 p
Total Cash (Recent Filing)£5.30M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)11.1
Beta0.63
Next Earnings
Oct 26, 2026EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend Yield8.33%
Share Statistics
EPS (TTM)1.42
Shares Outstanding5,224,860
10 Day Avg. Volume9,152
30 Day Avg. Volume7,851
Financial Highlights & Ratios
PEG Ratio-2.94
Price to Book (P/B)12.43
Price to Sales (P/S)10.95
P/FCF Ratio20.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA zero-debt balance sheet gives Bioventix durable financial flexibility: it can sustain dividends, fund development or opportunistic buybacks, and weather cyclical downturns without interest burden, supporting long-term capital allocation and downside protection.
Annity-like Royalty ModelRecurring royalties from tests that incorporate Bioventix antibodies create long-lived, volume-linked cash flows. Long assay lifecycles and partnerships with large IVD manufacturers provide structural revenue visibility and a durable earnings base once assays scale.
High Cash Conversion & ProfitabilityNear‑one FCF conversion and very high net margins indicate earnings reliably convert to cash, enabling sustainable dividends and low external financing needs. This quality of earnings supports long-term shareholder returns and operational resilience.
Bears Say
Revenue SlowdownA recent top-line decline signals weakening commercial momentum. For a royalty-driven model, reduced assay volumes or slower customer adoption can materially dent recurring revenue growth and future royalties, pressuring long-term cash flow expansion.
Shrinking Equity/Asset BaseA declining equity and asset base limits balance-sheet capacity to scale operations, absorb shocks or pursue inorganic growth. Over time this constrains investment flexibility and could amplify the impact of future revenue volatility on returns.
Geographic/Market Exposure RiskReported market pressure, notably in China, highlights concentration and external exposure. Reliance on a few large IVD partners and region-specific demand creates structural execution and regulatory risk that can reduce royalty streams if access or volumes falter.
Bioventix News
BVXP FAQ
What was Bioventix PLC’s price range in the past 12 months?
Bioventix PLC lowest share price was 1300.00 p and its highest was 2860.00 p in the past 12 months.
What is Bioventix PLC’s market cap?
Bioventix PLC’s market cap is £82.03M.
When is Bioventix PLC’s upcoming earnings report date?
Bioventix PLC’s upcoming earnings report date is Oct 26, 2026 which is in 101 days.
How were Bioventix PLC’s earnings last quarter?
Bioventix PLC released its earnings results on Mar 30, 2026. The company reported 0.684 p earnings per share for the quarter, beating the consensus estimate of 0.51 p by 0.174 p.
Is Bioventix PLC overvalued?
According to Wall Street analysts Bioventix PLC’s price is currently Overvalued.
Does Bioventix PLC pay dividends?
Bioventix PLC pays a Semiannually dividend of 70 p which represents an annual dividend yield of 8.33%. See more information on Bioventix PLC dividends here
What is Bioventix PLC’s EPS estimate?
Bioventix PLC’s EPS estimate is 0.66.
How many shares outstanding does Bioventix PLC have?
Bioventix PLC has 5,224,860 shares outstanding.
What happened to Bioventix PLC’s price movement after its last earnings report?
Bioventix PLC reported an EPS of 0.684 p in its last earnings report, beating expectations of 0.51 p. Following the earnings report the stock price went up 6.909%.
Which hedge fund is a major shareholder of Bioventix PLC?
Currently, no hedge funds are holding shares in GB:BVXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GB:BVXP Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth £28.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.51%
12-Months-Change
Fundamentals
Return on Equity
65.83%
Trailing 12-Months
Asset Growth
0.19%
Trailing 12-Months
Company Description
Bioventix PLC
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical areas such as thyroid conditions, vitamin D deficiencies, cardiac health markers, detection of drugs of abuse, fertility assessments, infectious diseases, oncology, and other diverse medical indications. Additionally, Bioventix PLC offers tailored contract SMA development and specialized recombinant services. The London, UK-based firm was established in 2003.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―